Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers

Drug resistance continues to be a major problem associated with cancer treatment. One of the primary causes of anticancer drug resistance is the frequently mutated RAS gene. In particular, considerable efforts have been made to treat KRAS-induced cancers by directly and indirectly controlling the activity of KRAS. However, the RAS protein is still one of the most prominent targets for drugs in cancer treatment. Recently, novel targeted protein degradation (TPD) strategies, such as proteolysis-targeting chimeras, have been developed to render “undruggable” targets druggable and overcome drug resistance and mutation problems. In this study, we discuss small-molecule inhibitors, TPD-based small-molecule chemicals for targeting RAS pathway proteins, and their potential applications for treating KRAS-mutant cancers. Novel TPD strategies are expected to serve as promising therapeutic methods for treating tumor patients with KRAS mutations.

[1]  E. Miyamoto-Sato,et al.  In vivo KRAS G12D/V degradation mediated by CANDDY using a modified proteasome inhibitor , 2022, bioRxiv.

[2]  A. Azmi,et al.  KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond. , 2021, Cancer treatment reviews.

[3]  Tao Wu,et al.  Solid Form Selection and Process Development of KO-947 Drug Substances , 2021 .

[4]  M. Ahmadian,et al.  Accessory proteins of the RAS-MAPK pathway: moving from the side line to the front line , 2021, Communications Biology.

[5]  S. Blacklow,et al.  Targeted degradation of the oncogenic phosphatase SHP2 , 2021, bioRxiv.

[6]  Jinyun Dong,et al.  PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy , 2021, Frontiers in Pharmacology.

[7]  Yan Niu,et al.  Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer. , 2021, European journal of medicinal chemistry.

[8]  Xiaomin Luo,et al.  Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders. , 2021, European journal of medicinal chemistry.

[9]  Lixia Chen,et al.  Novel PROTACs for degradation of SHP2 protein. , 2021, Bioorganic chemistry.

[10]  F. Blackhall,et al.  Mechanisms of Resistance to KRASG12C Inhibitors , 2021, Cancers.

[11]  Xian Chen,et al.  Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders. , 2020, Journal of medicinal chemistry.

[12]  Michael K. Wendt,et al.  SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer , 2020, Oncogene.

[13]  J. Riess,et al.  Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling , 2020, European Journal of Cancer.

[14]  K. Shokat,et al.  GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf , 2020, ACS central science.

[15]  Sarah L. Williams,et al.  Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer. , 2020, Journal of medicinal chemistry.

[16]  N. Rosen,et al.  Mutant-selective degradation by BRAF-targeting PROTACs , 2020, Nature Communications.

[17]  M. Vanoni,et al.  Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas , 2020, Molecular Cancer Therapeutics.

[18]  Xiao-Feng Xiong,et al.  Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies , 2020, Acta pharmaceutica Sinica. B.

[19]  A. Adjei,et al.  KRAS: From undruggable to a druggable Cancer Target. , 2020, Cancer treatment reviews.

[20]  F. McCormick,et al.  RAS-targeted therapies: is the undruggable drugged? , 2020, Nature Reviews Drug Discovery.

[21]  R. Goody,et al.  KRasG12C inhibitors in clinical trials: a short historical perspective , 2020, RSC medicinal chemistry.

[22]  A. Giobbie-Hurder,et al.  A phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma. , 2020, Journal of Clinical Oncology.

[23]  Mingliang Wang,et al.  Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein. , 2020, Journal of medicinal chemistry.

[24]  C. Crews,et al.  Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs , 2020, ACS central science.

[25]  Xiuyun Sun,et al.  PROTACs As Potential Therapeutic Agents for Cancer Drug Resistance. , 2020, Biochemistry.

[26]  Tatu Pantsar.  The current understanding of KRAS protein structure and dynamics , 2019, Computational and structural biotechnology journal.

[27]  David A. Scott,et al.  Exploring Targeted Degradation Strategy for Oncogenic KRASG12C. , 2019, Cell chemical biology.

[28]  M. Perry,et al.  Design, synthesis and biological evaluation of MEK PROTACs. , 2019, Journal of medicinal chemistry.

[29]  Xian Chen,et al.  Discovery of a First-in-class Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Degrader. , 2019, Journal of medicinal chemistry.

[30]  Neil Vasan,et al.  A view on drug resistance in cancer , 2019, Nature.

[31]  J. Desai,et al.  The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity , 2019, Nature.

[32]  B. Druker,et al.  Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation. , 2019, Cancer research.

[33]  M. Koegl,et al.  Drugging an undruggable pocket on KRAS , 2019, Proceedings of the National Academy of Sciences.

[34]  S. Gou,et al.  Pomalidomide hybrids act as proteolysis targeting chimeras: Synthesis, anticancer activity and B-Raf degradation. , 2019, Bioorganic chemistry.

[35]  R. Sullivan,et al.  A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts). , 2019, Journal of Clinical Oncology.

[36]  Amit K. Gupta,et al.  Discovery of High-Affinity Noncovalent Allosteric KRAS Inhibitors That Disrupt Effector Binding , 2019, ACS omega.

[37]  S. Phillips,et al.  Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds , 2019, Proceedings of the National Academy of Sciences.

[38]  L. Paz-Ares,et al.  KRAS-Mutant non-small cell lung cancer: From biology to therapy. , 2018, Lung cancer.

[39]  Matthew W. Boudreau,et al.  Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation. , 2018, Cell chemical biology.

[40]  G. Kiss,et al.  RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers , 2018, Nature Cell Biology.

[41]  W. R. Bishop,et al.  Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. , 2018, JCI insight.

[42]  P. Zarrinkar,et al.  Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor , 2018, Cell.

[43]  Y. Li,et al.  Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells , 2017, Front. Pharmacol..

[44]  P. Poulikakos,et al.  New perspectives for targeting RAF kinase in human cancer , 2017, Nature Reviews Cancer.

[45]  B. Neel,et al.  SHP2 Is Required for BCR-ABL1-Induced Hematologic Neoplasia , 2017, Leukemia.

[46]  Matthew E. Welsch,et al.  Multivalent Small-Molecule Pan-RAS Inhibitors , 2017, Cell.

[47]  T. Heightman,et al.  Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras , 2016, ACS central science.

[48]  Ping Zhu,et al.  Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases , 2016, Nature.

[49]  C. Der,et al.  RAS isoforms and mutations in cancer at a glance , 2016, Journal of Cell Science.

[50]  John C. Hunter,et al.  Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations , 2015, Molecular Cancer Research.

[51]  M. Dobre,et al.  Prognostic significance of KRAS gene mutations in colorectal cancer - preliminary study , 2014, Journal of medicine and life.

[52]  Roland Seifert,et al.  Faculty Opinions recommendation of K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. , 2013 .

[53]  Kevan M. Shokat,et al.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.

[54]  Shaji K. Kumar,et al.  Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs , 2010, Oncogene.

[55]  David T. Barkan,et al.  Global Sequencing of Proteolytic Cleavage Sites in Apoptosis by Specific Labeling of Protein N Termini , 2008, Cell.

[56]  Benjamin F. Cravatt,et al.  Global Mapping of the Topography and Magnitude of Proteolytic Events in Apoptosis , 2008, Cell.

[57]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[58]  J. Fernandez-Banet,et al.  The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients. , 2019, Cancer discovery.

[59]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.

[60]  C. Bowden,et al.  Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. , 2001, Cancer research.

[61]  L. Perkins,et al.  Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex. , 1997, Bioorganic & medicinal chemistry.